| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner | Director
14 companies
Makhzoumi Mohamad serves as a 10% Owner at SVRA and has filed Form 4s across 14 companies. Across recent SEC filings that breaks down to 16 buys and 4 sells. Those positions are worth an estimated $182.4M at current prices.
Historically, Makhzoumi Mohamad's trades have earned a middling insider score of 56/100 across 11 rated trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of -19.4%.
The biggest single holding is SVRA (~$73.4M) as 10% Owner. Net of sales, the recent Form 4 record there shows accumulation of 333,333 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 28, 2021 | GLUE Monte Rosa Therapeutics, Inc. | 10% Owner | Buy | 1,050,000 | $19.00 | $19,950,000.00 | +15.8% | +28.8% | -49.9% | |
| Jun 28, 2021 | NEUE Neuehealth, Inc. | Director, 10% Owner | Buy | 1,944,444 | $18.00 | $34,999,992.00 | +8.8% | - | - | |
| Mar 16, 2021 | MRKR Marker Therapeutics, Inc. | 10% Owner | Buy | 5,714,285 | $1.75 | $9,999,998.75 | +114.3% | +91.4% | -77.7% | |
| Jul 14, 2020 | NKTX Nkarta, Inc. | 10% Owner | Buy | 666,666 | $18.00 | $11,999,988.00 | +29.8% | - | - | |
| Apr 3, 2020 | TRVI Trevi Therapeutics, Inc. | 10% Owner | Sell | 564 | $2.66 | $1,500.24 | - | - | - | |
| Jul 22, 2019 | MIRM Mirum Pharmaceuticals, Inc. | 10% Owner | Buy | 450,000 | $15.00 | $6,750,000.00 | +12.0% | - | - | |
| May 9, 2019 | TRVI Trevi Therapeutics, Inc. | 10% Owner | Buy | 2,500,000 | $10.00 | $25,000,000.00 | +129.0% | - | - |